All In Biotech

Drug Trial Radar · NCT05228470

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

A PHASE 1B/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF ELRANATAMAB (PF-06863135) IN CHINESE PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY (TRIPLE-CLASS REFRACTORY MM)

Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

39

Actual

Start

Dec 21, 2021

Primary completion

Aug 6, 2023

Study completion Sep 11, 2025

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Feb 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to understand the study medicine (called Elranatamab, or PF-06863135) as potential treatment for refractory multiple myeloma. Multiple myeloma is a form of cancer in the bone that forces healthy blood cells to go out. Sometimes, multiple myeloma does not respond to current therapy or quickly progresses, and this is called refractory multiple myeloma. Elranatamab is a study medicine that target multiple myeloma and activates the human body to fight against this disease. We are seeking Chinese participants to take part in this study. The study will be 2 parts, called part 1b and part 2. In part 1b, participants will receive Elranatamab at 2 steps priming and full dose as a sc (subcutaneous injection) therapy. We will monitor participants' safety and reactions to the study medicine. This will help us understand the dosage of Elranatamab to be used safely. In part 2 of the study, participants will receive Elranatamab and their multiple myeloma growth will be monitored. This will help us understand if Elranatamab, when used alone, may be a therapy for refractory multiple myeloma. Participants in this part of the study are expected to take part for about 2 years.

Conditions

  • Elranatamab
  • Myeloma
  • Multiple Myeloma
  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma
  • PF-06863135
  • BCMA
  • Bispecific
  • Bispecific Antibody
  • BCMA-CD3 Bispecific
  • MagnetisMM-8

Interventions

  • ElranatamabDrug

    BCMA-CD3 bispecific antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT)Time frame: Cycle 1 (28 days)
  2. Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) as Per International Myeloma Working Group (IMWG) CriteriaTime frame: From date of first dose until confirmed disease progression (PD), death, start of new anticancer therapy, whichever occurred first (approximately up to 16 months)

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Gaobo Boren Hospital

    Beijing, China

  • Peking University Third Hospital

    Beijing, China

  • Peking Union Medical College Hospital

    Beijing, China

  • Hematology Hospital, Chinese Academy of Medical Sciences

    Tianjin, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • Shenzhen Second People's Hosptial

    Shenzhen, Guangdong, China

  • Harbin First Hospital

    Harbin, Heilongjiang, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Nanjing Drum Tower Hospital,The Affiliated Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • Shandong Provincial Hospital

    Jinan, Shandong, China

  • The First Affiliated Hospital of College of Medicine, Zhejiang University

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.